Charles Schwab
KLRS

Charles Schwab’s Kalaris Therapeutics KLRS Stock Holding History

Charles Schwab’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,481
Closed -$46.1K – 3523
2024
Q3 		$46.1K Sell
2,481
-12,500
-83% -$219K ﹤0.01% 3421
2024
Q2 		$249K Sell
14,981
-5,055
-25% -$89.2K ﹤0.01% 3406
2024
Q1 		$348K Sell
20,036
-652
-3% -$10.6K ﹤0.01% 3143
2023
Q4 		$323K Buy
20,688
+2,741
+15% +$108K ﹤0.01% 3205
2023
Q3 		$887K Buy
17,947
+3,561
+25% +$243K ﹤0.01% 2840
2023
Q2 		$1.12M Buy
14,386
+1,160
+9% +$110K ﹤0.01% 2727
2023
Q1 		$1.2M Buy
13,226
+32
+0.2% +$4.08K ﹤0.01% 2681
2022
Q4 		$1.56M Buy
13,194
+191
+1% +$32.4K ﹤0.01% 2636
2022
Q3 		$2.36M Buy
13,003
+3,519
+37% +$548K ﹤0.01% 2539
2022
Q2 		$851K Buy
9,484
+566
+6% +$59.3K ﹤0.01% 2855
2022
Q1 		$1.39M Sell
8,918
-144
-2% -$28.7K ﹤0.01% 2752
2021
Q4 		$2.7M Buy
9,062
+186
+2% +$86.3K ﹤0.01% 2600
2021
Q3 		$5.12M Buy
8,876
+2,693
+44% +$1.25M ﹤0.01% 2366
2021
Q2 		$2.81M Sell
6,183
-32
-0.5% -$16.5K ﹤0.01% 2608
2021
Q1 		$3.35M Buy
6,215
+1,286
+26% +$1.08M ﹤0.01% 2491
2020
Q4 		$4.36M Buy
4,929
+171
+4% +$132K ﹤0.01% 2289
2020
Q3 		$3.01M Buy
+4,758
New +$3.25M ﹤0.01% 2327

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab's KLRS Position: Q4 2024 in Review

Charles Schwab sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 2,481 shares — an estimated $46.1K sold.

Charles Schwab first reported a position in KLRS in Q3 2020 and held it in 17 quarters. The position peaked at $5.12M in Q3 2021. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • Charles Schwab reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Charles Schwab sold 2,481 Kalaris Therapeutics shares in Q4 2024, an estimated $46.1K.
  • Charles Schwab first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 17 quarters.
  • Charles Schwab's Kalaris Therapeutics position peaked at $5.12M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.